New whitepaper: Increasing AAV titers through proprietary cell line development
AGC Biologics
We work side by side with our customers to improve patients’ lives by bringing new biopharmaceutical products to market.
The growing demand for adeno-associated viral (AAV) vectors in therapeutics has shown there is a need for scalable and efficient manufacturing systems. By first establishing a proprietary cell line, a developer can take advantage of substantial opportunities for achieving higher AAV titers and a product that scales at each critical clinical milestone.
In this white paper, one of our leading vector development scientists at our Milan Cell and Gene Center of Excellence, Silvia Ungari , addresses some common questions, challenges and best practices for developing proprietary AAV cell lines, including advantages of clonal selection, genetic engineering considerations, packaging/producer cell development, cost, access, and more.
How can establishing a proprietary cell line lead to increased AAV titers?
Establishing a proprietary cell line can enhance AAV titers through various strategies. The optimization of a cell line for AAV production often involves genetic engineering or, more commonly, the selection of clones from a bulk population with improved viral proteins expression, or packaging efficiency, or other positive mechanisms resulting in an overall increased productivity. The advantage of this latest approach is that…
Visit our website at the link below to download the full article.
#AAV #CellLineDevelopment #CellandGene #Pharma #Biotechnology #yourfriendlyCDMOexpert